Literature DB >> 1912834

Survival with bladder cancer, evaluation of delay in treatment, type of surgeon, and modality of treatment.

M C Gulliford1, A Petruckevitch, P G Burney.   

Abstract

OBJECTIVE: To determine whether length of delay before treatment; specialty and grade of the surgeon; and use made of surgery, radiotherapy, and chemotherapy influenced the survival of patients with cancer of the bladder, after adjusting for case severity.
DESIGN: Retrospective cohort study.
SETTING: South East and South West Thames health regions. PATIENTS: 609 men aged under 75 resident in the South Thames regions who had been registered as new cases of bladder cancer in 1982, 35 of whom were excluded, leaving 574 eligible patients. Analysis was based on 75% retrieval rate for case notes. MAIN OUTCOME MEASURES: Duration of survival from date of diagnosis of the bladder tumour.
RESULTS: 10 prognostic variables were used to adjust for case severity. The median delay from referral to first treatment was 48 (interquartile range 27-84) days. Treatment after a short delay was associated with shorter survival because of the early treatment of more severe cases. Consultants treated 68% of patients, trainee surgeons treated less severe cases. Initial treatment was by a urologist in 67% of cases, but the specialty of the surgeon was not associated with prognosis. The associations of radiotherapy, cystectomy, and systemic chemotherapy with survival were interpreted in terms of selection bias as well as therapeutic effect.
CONCLUSION: Case severity was the most important influence on survival and influenced length of delay before treatment, grade and specialty of the surgeon, and main treatment allocation. After adjusting for case severity variations in these processes of care were not strongly associated with variations in survival.

Entities:  

Mesh:

Year:  1991        PMID: 1912834      PMCID: PMC1670565          DOI: 10.1136/bmj.303.6800.437

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  18 in total

Review 1.  Biology and management of bladder cancer.

Authors:  D Raghavan; W U Shipley; M B Garnick; P J Russell; J P Richie
Journal:  N Engl J Med       Date:  1990-04-19       Impact factor: 91.245

Review 2.  The dangers of a long urological waiting list.

Authors:  M C Bishop
Journal:  Br J Urol       Date:  1990-05

Review 3.  Prognostic indices in transitional cell carcinoma of the bladder.

Authors:  P D Abel
Journal:  Br J Urol       Date:  1988-08

4.  Explaining variations in hospital death rates. Randomness, severity of illness, quality of care.

Authors:  R E Park; R H Brook; J Kosecoff; J Keesey; L Rubenstein; E Keeler; K L Kahn; W H Rogers; M R Chassin
Journal:  JAMA       Date:  1990-07-25       Impact factor: 56.272

5.  Invasive bladder cancer. Prognostic factors and results of radiotherapy with and without cystectomy.

Authors:  H Mameghan; R Fisher
Journal:  Br J Urol       Date:  1989-03

6.  Prognostic factors in superficial bladder cancer.

Authors:  Y Aso; L Anderson; M Soloway; C Bouffioux; G Chisholm; F Debruyne; T Kawai; K H Kurth; A Maru; W G Straffon
Journal:  Prog Clin Biol Res       Date:  1986

7.  Hospital inpatient mortality. Is it a predictor of quality?

Authors:  R W Dubois; W H Rogers; J H Moxley; D Draper; R H Brook
Journal:  N Engl J Med       Date:  1987-12-24       Impact factor: 91.245

8.  Geographical variation in mortality from conditions amenable to medical intervention in England and Wales.

Authors:  J R Charlton; R M Hartley; R Silver; W W Holland
Journal:  Lancet       Date:  1983-03-26       Impact factor: 79.321

9.  The importance of severity of illness in assessing hospital mortality.

Authors:  J Green; N Wintfeld; P Sharkey; L J Passman
Journal:  JAMA       Date:  1990-01-12       Impact factor: 56.272

10.  T3 bladder cancer: salvage rather than elective cystectomy after radiotherapy.

Authors:  H F Hope-Stone; R T Oliver; H R England; J P Blandy
Journal:  Urology       Date:  1984-10       Impact factor: 2.649

View more
  20 in total

1.  The reliability of cancer registry records.

Authors:  M Gulliford
Journal:  Qual Health Care       Date:  1996-06

2.  Impact of preoperative wait time on survival in patients with clinical stage II/III gastric cancer.

Authors:  Kenichiro Furukawa; Tomoyuki Irino; Rie Makuuchi; Yusuke Koseki; Kenichi Nakamura; Yuhei Waki; Keiichi Fujiya; Hayato Omori; Yutaka Tanizawa; Etsuro Bando; Taiichi Kawamura; Masanori Terashima
Journal:  Gastric Cancer       Date:  2018-12-10       Impact factor: 7.370

3.  Clinical oncology information network.

Authors:  S J Karp
Journal:  BMJ       Date:  1994-01-15

4.  Differences in mortality after fracture of hip. Casemix factors may not have been considered sufficiently.

Authors:  C J Packham
Journal:  BMJ       Date:  1995-08-26

5.  Collecting data on cancer.

Authors:  I Basnett; A M Pollock; M Gill
Journal:  BMJ       Date:  1994-03-19

6.  The haematuria clinic.

Authors:  P Marazzi; R Gabriel
Journal:  BMJ       Date:  1994-02-05

7.  Cancer diagnostic tools to aid decision-making in primary care: mixed-methods systematic reviews and cost-effectiveness analysis.

Authors:  Antonieta Medina-Lara; Bogdan Grigore; Ruth Lewis; Jaime Peters; Sarah Price; Paolo Landa; Sophie Robinson; Richard Neal; William Hamilton; Anne E Spencer
Journal:  Health Technol Assess       Date:  2020-11       Impact factor: 4.014

8.  An analysis of preoperative delays prior to radical cystectomy for bladder cancer in Quebec.

Authors:  Nader Fahmy; Wassim Kassouf; Suganthiny Jeyaganth; Moamen Amin; Salaheddin Mahmud; Jordan Steinberg; Simon Tanguay; Armen Aprikian
Journal:  Can Urol Assoc J       Date:  2008-04       Impact factor: 1.862

9.  Can efficiency of follow-up for superficial bladder cancer be increased?

Authors:  M C Gulliford; A Petruckevitch; P G Burney
Journal:  Ann R Coll Surg Engl       Date:  1993-01       Impact factor: 1.891

10.  Survival analysis of patients with bladder cancer, life table approach.

Authors:  Abbas Rezaianzadeh; Abolfazl Mohammadbeigi; Jafar Mobaleghi; Narges Mohammadsalehi
Journal:  J Midlife Health       Date:  2012-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.